85021938 - G

Information

  • Trademark
  • 85021938
  • Serial Number
    85021938
  • Registration Number
    4133826
  • Filing Date
    April 23, 2010
    14 years ago
  • Registration Date
    May 01, 2012
    12 years ago
  • Transaction Date
    January 15, 2019
    5 years ago
  • Status Date
    December 07, 2018
    6 years ago
  • Published for Opposition Date
    February 14, 2012
    12 years ago
  • Location Date
    May 01, 2012
    12 years ago
  • Status Code
    710
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    ERVIN, INGA MARIE
  • Attorney Docket Number
    140998
    Attorney Name
    Zachary A. Aria
    Law Office Assigned Location Code
    M20
  • Owners
Mark Drawing Code
3000
Mark Identification
G
Case File Statements
  • CC0000: Color is not claimed as a feature of the mark.
  • DM0000: The mark consists of the letter "G" with a dot.
  • GS0051: Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders and single gene disorders; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
  • GS0441: Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation
Case File Event Statements
  • 12/7/2018 - 6 years ago
    43 - CANCELLED SEC. 8 (6-YR) Type: C8..
  • 5/1/2017 - 7 years ago
    42 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1
  • 7/8/2014 - 10 years ago
    41 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 7/8/2014 - 10 years ago
    40 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 7/2/2014 - 10 years ago
    39 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN
  • 5/1/2012 - 12 years ago
    38 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 2/14/2012 - 12 years ago
    37 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/14/2012 - 12 years ago
    36 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/25/2012 - 12 years ago
    35 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/10/2012 - 12 years ago
    34 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 1/6/2012 - 12 years ago
    33 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 1/6/2012 - 12 years ago
    32 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 1/6/2012 - 12 years ago
    31 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 1/6/2012 - 12 years ago
    30 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/6/2012 - 12 years ago
    29 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/5/2012 - 12 years ago
    28 - PREVIOUS ALLOWANCE COUNT WITHDRAWN Type: ZZZX
  • 12/20/2011 - 13 years ago
    27 - WITHDRAWN FROM PUB - OG REVIEW QUERY Type: PBCR
  • 12/6/2011 - 13 years ago
    26 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 11/21/2011 - 13 years ago
    25 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/4/2011 - 13 years ago
    24 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 11/4/2011 - 13 years ago
    23 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/4/2011 - 13 years ago
    22 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 5/9/2011 - 13 years ago
    21 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/9/2011 - 13 years ago
    20 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/9/2011 - 13 years ago
    19 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/13/2011 - 13 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/13/2011 - 13 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/13/2011 - 13 years ago
    16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/4/2011 - 13 years ago
    15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/4/2011 - 13 years ago
    14 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/4/2011 - 13 years ago
    13 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/15/2011 - 13 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/15/2011 - 13 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/12/2011 - 13 years ago
    10 - ASSIGNED TO LIE Type: ALIE
  • 12/22/2010 - 14 years ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/20/2010 - 14 years ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/23/2010 - 14 years ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/23/2010 - 14 years ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 6/23/2010 - 14 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/22/2010 - 14 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/30/2010 - 14 years ago
    3 - NOTICE OF DESIGN SEARCH CODE MAILED Type: MDSC
  • 4/29/2010 - 14 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 4/27/2010 - 14 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP